Tumour-associated mast cells in classical Hodgkin's lymphoma: Correlation with histological subtype, other tumour-infiltrating inflammatory cell subsets and outcome

European Journal of Haematology

Volumn 96, Issue 3, 2016, Pages 252-259

  Andersen, Maja D ^a   Kamper, Peter ^a   Nielsen, Patricia S ^a   Bendix, Knud ^a   Riber Hansen, Rikke ^a   Steiniche, Torben ^a   Hamilton Dutoit, Stephen ^a   Clausen, Michael ^a   d'Amore, Francesco ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Classical Hodgkin's lymphoma; Mast cells; Mixed cellularity subtype; Prognosis; Tumour microenvironment

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; GRANZYME; PREDNISOLONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; BIOLOGICAL MARKER;

ADULT; ARTICLE; CANCER RADIOTHERAPY; CELL INFILTRATION; CLASSICAL HODGKIN LYMPHOMA; EVENT FREE SURVIVAL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; MACROPHAGE; MAJOR CLINICAL STUDY; MAST CELL; MULTIPLE CYCLE TREATMENT; NODULAR SCLEROSIS HODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; TISSUE MICROARRAY; ADOLESCENT; AGED; CANCER STAGING; CELL COUNT; FEMALE; HODGKIN DISEASE; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; REED STERNBERG CELL; SURVIVAL ANALYSIS; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; CELL COUNT; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGES; MALE; MAST CELLS; MIDDLE AGED; NEOPLASM STAGING; REED-STERNBERG CELLS; SURVIVAL ANALYSIS; TUMOR MICROENVIRONMENT; YOUNG ADULT;

EID: 84958121006     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12583     Document Type: Article

References (25)

1. Aldinucci D, Gloghini A, Pinto A, De FR, Carbone A. The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol 2010;221:248-63.
2. Barros MH, Vera-Lozada G, Soares FA, Niedobitek G, Hassan R. Tumor microenvironment composition in pediatric classical Hodgkin lymphoma is modulated by age and Epstein-Barr virus infection. Int J Cancer 2012;131:1142-52.
3. Kamper P, Bendix K, Hamilton-Dutoit S, Honore B, Nyengaard JR, d'Amore F. Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma. Haematologica 2011;96:269-76.
4. Alvaro T, Lejeune M, Salvado MT, Bosch R, Garcia JF, Jaen J, Banham AH, Roncador G, Montalban C, Piris MA. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 2005;11:1467-73.
5. Enblad G, Sundstrom C, Glimelius B. Infiltration of eosinophils in Hodgkin's disease involved lymph nodes predicts prognosis. Hematol Oncol 1993;11:187-93.
6. Ribatti D, Crivellato E. Mast cells, angiogenesis and cancer. Adv Exp Med Biol 2011;716:270-88.
7. Molin D, Edstrom A, Glimelius I, Glimelius B, Nilsson G, Sundstrom C, Enblad G. Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma. Br J Haematol 2002;119:122-4.
8. Glimelius I, Rubin J, Rostgaard K, et al. Predictors of histology, tissue eosinophilia and mast cell infiltration in Hodgkin's lymphoma-a population-based study. Eur J Haematol 2011;87:208-16.
9. Keresztes K, Szollosi Z, Simon Z, Tarkanyi I, Nemes Z, Illes A. Retrospective analysis of the prognostic role of tissue eosinophil and mast cells in Hodgkin's lymphoma. Pathol Oncol Res 2007;13:237-42.
10. Molin D, Fischer M, Xiang Z, Larsson U, Harvima I, Venge P, Nilsson K, Sundstrom C, Enblad G, Nilsson G. Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease. Br J Haematol 2001;114:616-23.
11. International Agency for Research in Cancer (IARC). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. Lyon, France: International Agency for Research in Cancer (IARC), 2008.
12. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
13. Erichsen R, Lash TL, Hamilton-Dutoit SJ, Bjerregaard B, Vyberg M, Pedersen L. Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank. Clin Epidemiol 2010;2:51-6.
14. Tzankov A, Went P, Zimpfer A, Dirnhofer S. Tissue microarray technology: principles, pitfalls and perspectives-lessons learned from hematological malignancies. Exp Gerontol 2005;40:737-44.
15. Gulley ML, Glaser SL, Craig FE, Borowitz M, Mann RB, Shema SJ, Ambinder RF. Guidelines for interpreting EBER in situ hybridization and LMP1 immunohistochemical tests for detecting Epstein-Barr virus in Hodgkin lymphoma. Am J Clin Pathol 2002;117:259-67.
16. Sharma VK, Agrawal A, Pratap VK, Nagar AM, Mehrotra ML. Mast cell reactivity in lymphoma: a preliminary communication. Indian J Cancer 1992;29:61-5.
17. Groot KT, Abudukelimu A, Redegeld FA. Mast cells as target in cancer therapy. Curr Pharm Des 2009;15:1868-78.
18. Oldford SA, Marshall JS. Mast cells as targets for immunotherapy of solid tumors. Mol Immunol 2015;63:113-24.
19. Glimelius I, Edstrom A, Fischer M, Nilsson G, Sundstrom C, Molin D, Amini RM, Enblad G. Angiogenesis and mast cells in Hodgkin lymphoma. Leukemia 2005;19:2360-2.
20. Mizuno H, Nakayama T, Miyata Y, Saito S, Nishiwaki S, Nakao N, Takeshita K, Naoe T. Mast cells promote the growth of Hodgkin's lymphoma cell tumor by modifying the tumor microenvironment that can be perturbed by bortezomib. Leukemia 2012;26:2269-76.
21. DeBruin EJ, Gold M, Lo BC, Snyder K, Cait A, Lasic N, Lopez M, McNagny KM, Hughes MR. Mast cells in human health and disease. Methods Mol Biol 2015;1220:93-119.
22. Gruber BL. Mast cells in the pathogenesis of fibrosis. Curr Rheumatol Rep 2003;5:147-53.
23. Hugle T. Beyond allergy: the role of mast cells in fibrosis. Swiss Med Wkly 2014;144:w13999.
24. Pistorio AL, Ehrlich HP. Modulatory effects of connexin-43 expression on gap junction intercellular communications with mast cells and fibroblasts. J Cell Biochem 2011;112:1441-9.
25. Ohri CM, Shikotra A, Green RH, Waller DA, Bradding P. Tumour necrosis factor-alpha expression in tumour islets confers a survival advantage in non-small cell lung cancer. BMC Cancer 2010;10:323.